Liver Disease Clinical Trials

Showing 1041-1060 of 1,498 trials

Endoscopic Variceal Ligation in Children

NCT03943784

This is an ambispective single-center cohort study of pediatric patients with portal hypertension and esophageal varices. The study was designed to evaluate the efficacy and safety of primary prophylaxis with endoscopic variceal ligation to prevent upper gastrointestinal bleeding compared to non-selected beta-blockers prophylaxis.

Esophageal Varices in Cirrhosis of the LiverUpper Gastrointestinal BleedingEndoscopy+1 more

Hospital Vall d'Hebron60 participantsStarted Jan 2014

COMPLETED

Association Between Nonalcoholic Fatty Liver Disease and Acute Pancreatitis

NCT03566173

The early evaluation of AP severity are vital. Previous studies have shown non-alcoholic fatty liver disease (NAFLD) is associated with severity of acute pancreatitis (AP). This study is aimed to investigate the relationship between NAFLD and AP severity.

Acute PancreatitisNonalcoholic Fatty Liver Disease

Ningbo No. 1 Hospital1,662 participantsStarted Mar 2018

Ningbo, Zhejiang, China

COMPLETEDPhase 4

Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

NCT02304159

This is a randomized, open label, single center safety and efficacy study. At least 40 cirrhotic subjects with HCV genotype 3 will receive standard of care treatment of sofosbuvir and ribavirin (SOF/RBV) as well as 60 mg daily of Daclatasvir (investigational product). Subjects will be randomized in a 1:1 to receive either: * Group A: 16 weeks of DCV/SOF/RBV * Group B: 24 weeks of DCV/SOF/RBV Subjects will return to the study center at various time points throughout the 16 or 24 weeks of treatment in addition to 12 weeks post taking last dose of study drug to monitor safety and efficacy. These visits will be according to standard of care.

Hepatitis CCirrhosis

Tarek I. Hassanein, M.D., FACP, FAG, AGAF39 participantsStarted Jan 2015

Coronado, California, United States

Endoscopic Variceal Ligation in Children

Association Between Nonalcoholic Fatty Liver Disease and Acute Pancreatitis

Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

Related Searches

Kuopio Ischaemic Heart Disease Risk Factor Study (Nutrition Component)

Early Use of TIPSS in Patients With Cirrhosis and Variceal Bleeding

Hydrogen-rich Water for Non-alchoholic Fatty Liver Disease

Effect of Exercise on Hepatic Fat in Overweight Children

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular Carcinoma

Usefulness of Non-contrast MagnetIc Resonance imAging Versus Non-Contrast Ultrasonography for surveiLlancE of HepatoCellular Carcinoma [MIRACLE-HCC]

Measuring Fatty Liver With Ultrasound and MRS in Children With Overweight or Obesity

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD

Effect of Modified Time-restricted Feeding in Preventing Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

Using Addiction Comprehensive Health Enhancement Support System (ACHESS) in an Alcoholic Liver Disease Population

Evaluating Alcohol Use in Alcoholic Liver Disease

Assessing Cirrhosis Quality of Care While Accounting for Cost

Feasibility of VIIT in Adults With NASH